ArticleOTO open
Pooled Analysis of Sleep Outcomes After Treatment With Temperature-Controlled Radiofrequency in Nasal Airway Obstruction Patients.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the long-term impact of temperature-controlled radiofrequency (TCRF) treatment on sleep-related symptoms in patients with nasal airway obstruction (NAO), including those with documented obstructive sleep apnea (OSA). Study Design: Pooled analysis of prospective multicenter studies. Setting: Seven academic and 25 private otolaryngology sites. Methods: A pooled analysis of 345 adults across four prospective multicenter studies (PIVOTAL, VATRAC, SWELL, and AERWAY) from 7 academic and 25 private otolaryngology sites was conducted. Participants had severe-to-extreme NAO and received a single, office-based TCRF treatment targeting the nasal valve or septal swell body (SSB). Outcomes included sleep-related components of the Nasal Obstruction Symptom Evaluation (NOSE) scale, 22-item Sino-Nasal Outcome Test (SNOT-22) sleep domain, and Epworth Sleepiness Scale (ESS). Analyses included stratification by the presence or absence of OSA and linear regression. Results: TCRF treatment was associated with significant, durable improvements in sleep-related symptoms through 24 months. At 24 months, the "Trouble Sleeping" subcomponent of the NOSE score improved by -1.9 (95% CI, -2.0 to -1.7) points, a 64% improvement. SNOT-22 sleep domain scores declined by -9.0 (95% CI, -10.5 to -7.6) points, with more than 80% of participants achieving clinical improvement. Among those with excessive daytime sleepiness (ESS ≥ 10), ESS dropped by -8.3 (95% CI, -9.7 to -6.9), and the prevalence of sleepiness fell from 53.8% to 9.8%. Improvements were consistent across the OSA+ subgroup. Conclusion: Office-based TCRF therapy targeting the nasal valve and/or SSB is associated with clinically meaningful, durable improvements in sleep-related symptoms and daytime somnolence in NAO patients, including a subset of those with documented OSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.